Medindia

X

Rs.7 Diabetes Drug Boosts the Cost-Effectiveness of Pharma Market in India

by Reshma Anand on  November 21, 2015 at 12:06 PM Diabetes News   - G J E 4
Anti-diabetic drug market has been potentially growing in India. As several drugs have been launched by various Indian pharmaceutical companies, Zydus Cadila has made a breakthrough in the diabetes drug market by launching its new drug at the most affordable cost.
Rs.7 Diabetes Drug Boosts the Cost-Effectiveness of Pharma Market in India
Rs.7 Diabetes Drug Boosts the Cost-Effectiveness of Pharma Market in India
Advertisement

Cadila has offered its drug Tenglyn, the generic version of oral anti-diabetic drug gliptins at a price of Rs. 7 per tablet in India. Gliptins have been ruling the diabetes market with its potential to induce insulin in the blood. Several pharma companies like Glenmark, Ajanta are already selling the same drug at a cost of Rs. 20 per tablet.

‘The new anti-diabetic drug, Tenglyn offered at a price of rs.7 per tablet will be a boon for 60 million diabetic patients in India.’
Advertisement
"With Tenglyn we provide patients suffering from diabetes access to this advanced treatment at the most affordable cost," said Sharvil Patel, Deputy Managing Director, Zydus Cadila.

Therefore, this new launch of the same drug at a cost of rs.7 will help 60 million diabetic patients economically. The cost-effective drug will also be made easily accessible all over the country. The price of Zydus is said to be one sixth of all other pharmaceutical companies.

Source: Medindia
Advertisement

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
Notify me when reply is posted I agree to the terms and conditions

You May Also Like

Advertisement
View All